Adjuvant anti-HER2 therapy after early HER2-positive breast cancer surgery
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies a second anti-HER2 treatment (given after surgery) to help lower the risk of breast cancer coming back in people with very small, node-negative, HER2-positive tumors. It will also closely monitor heart function and other side effects because these medicines can affect the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman age 18–70.
- You have finished surgery for breast cancer (radical operation) and have had it recently (within 84 days).
- Your tumor is invasive ductal breast cancer that is very small (under 8 mm) and has no lymph node involvement (node-negative) and no signs of spread.
- Your tumor must test HER2-positive, using either specific lab staining or gene testing results, and meet a defined tumor grade (nuclear grade 3).
- You must have been able to use your removed tumor tissue for required lab testing, and there is enough tissue for multiple sample checks.
- Your health checks must be safe for treatment: good heart function (left-ventricle pumping at least 50%), good blood/liver/kidney clotting labs, and a strong overall performance status (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.